Atherosclerotic Cardiovascular Disease Market to Witness Robust Expansion Through 2034, Driven by Key Players Like Merck, NewAmsterdam Pharma, and Amgen | DelveInsight

Atherosclerotic Cardiovascular Disease (ASCVD) remains a leading cause of morbidity and mortality worldwide, posing a substantial burden on healthcare systems despite advancements in prevention and management. Characterized by plaque buildup within arterial walls, ASCVD encompasses a spectrum of conditions including coronary artery disease, peripheral artery disease, and cerebrovascular disease. It significantly increases the risk of heart attacks, strokes, and cardiovascular death, especially among aging populations and individuals with comorbidities such as diabetes and hypertension.

DelveInsight's comprehensive report, "Atherosclerotic Cardiovascular Disease - Market Insight, Epidemiology, and Market Forecast - 2034," delivers a detailed analysis of the disease's burden and evolving therapeutic landscape across major markets, including the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The report offers thorough segmentation by age, risk factors, and comorbidities, alongside historical and projected epidemiological data.

While statins remain the cornerstone of lipid-lowering therapy, recent years have witnessed significant advancements in ASCVD management with the advent of PCSK9 inhibitors, bempedoic acid, and anti-inflammatory therapies. However, challenges such as therapeutic inertia, under-diagnosis in asymptomatic patients, and poor adherence to long-term therapy persist across populations.

The ASCVD market is projected to expand steadily through 2034, fueled by an aging global population, increased screening and awareness, and the launch of innovative therapies targeting residual cardiovascular risk beyond cholesterol control. Ongoing research in RNA-based therapies, anti-inflammatory agents, and combination drug regimens holds promise to redefine treatment paradigms.

DelveInsight anticipates a dynamic and competitive market over the next decade, with substantial opportunities for pharmaceutical innovators, cardiology specialists, and public health stakeholders. As the burden of cardiovascular disease continues to climb, the ASCVD market is poised for meaningful transformation, driven by scientific innovation, preventive strategies, and a growing emphasis on personalized cardiovascular care.

Request a sample and uncover the latest breakthroughs shaping the atherosclerotic cardiovascular disease market landscape and future outlook @ https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the Atherosclerotic Cardiovascular Disease Market Report:
• The 7MM atherosclerotic cardiovascular disease treatment market was valued at approximately USD 23 billion in 2023 and is expected to grow during the forecast period.
• The atherosclerotic cardiovascular disease market size was highest in the US among the 7MM, reaching approximately USD 12 billion in 2023, and is projected to grow at a CAGR of 2.8% through 2034.
• The 7MM ASCVD market was valued at USD 23 billion in 2023, led by statins, ezetimibe/bempedoic acid, and PCSK9 inhibitors, and is expected to grow at a 2.2% CAGR with new therapies from 2024 to 2034.
• According to DelveInsight, there were about 55.7 million diagnosed prevalent cases of ASCVD in the 7MM in 2023.
• The US accounted for the highest number of diagnosed ASCVD cases in 2023, with around 26 million, and this number is expected to rise.
• Among the EU countries, Germany had the highest diagnosed ASCVD population (~5 million), followed by France (~4 million), while Spain had the lowest (~3 million) in 2023.
• In January 2025, the FDA granted 510(k) clearance to Roche's Tina-quant® Lipoprotein (a) Gen.2 Molarity assay. This marks the first blood test in the US cleared to measure lipoprotein (a) [Lp(a)] in molar units. The assay can aid in evaluating lipid metabolism disorders and assessing atherosclerotic cardiovascular disease (ASCVD) risk when used alongside clinical assessments and other lipoprotein tests.
• In August 2024, Novartis announced that the Phase III V-MONO study of LEQVIO (inclisiran) met its primary endpoints. The study demonstrated that twice-yearly Leqvio significantly reduced low-density lipoprotein cholesterol (LDL-C) compared to placebo and ezetimibe in patients at low or moderate risk of atherosclerotic cardiovascular disease (ASCVD).
• Emerging therapies for atherosclerotic cardiovascular disease include Olpasiran (AMG 890), MK-0616, Obicetrapib (TA-8995), and others.
• Key companies involved in the treatment of atherosclerotic cardiovascular disease include Merck Sharp & Dohme Corp, NewAmsterdam Pharma, Amgen Inc., and others.

To know in detail about the atherosclerotic cardiovascular disease market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerotic Cardiovascular Disease Overview
Atherosclerotic Cardiovascular Disease (ASCVD) is a chronic condition marked by the gradual buildup of plaque within the arterial walls, leading to the narrowing and hardening of arteries. This process restricts blood flow and increases the risk of life-threatening events such as heart attacks, strokes, and peripheral artery disease. ASCVD is driven by a complex interplay of risk factors, including high cholesterol, hypertension, smoking, diabetes, obesity, and sedentary lifestyle, along with genetic predisposition. It often remains silent in the early stages, with symptoms appearing only as the disease progresses, depending on the arteries involved.

Diagnosis typically involves a combination of blood tests, imaging, and cardiac evaluations, while treatment is centered on aggressive risk factor management through medications and lifestyle changes. Statins, antihypertensives, and antiplatelet agents are commonly prescribed, and in advanced cases, revascularization procedures like angioplasty or bypass surgery may be required. Although there is no cure, ASCVD is manageable, and early intervention significantly reduces the risk of severe complications and improves long-term outcomes.

Get a free sample for the atherosclerotic cardiovascular disease market forecast, size & share analysis report: https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerotic Cardiovascular Disease Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Atherosclerotic Cardiovascular Disease Epidemiology Segmentation:
The atherosclerotic cardiovascular disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease
• Gender-Specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease
• Age-Specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease
• Comorbidity-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Disease Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for atherosclerotic cardiovascular disease throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Atherosclerotic cardiovascular disease drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for atherosclerotic cardiovascular disease, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of atherosclerotic cardiovascular disease therapeutics.

Explore how emerging atherosclerotic cardiovascular disease therapies are aligning with evolving patient populations @ https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerotic Cardiovascular Disease Market Outlook
With the anticipated introduction of novel therapies such as Olpasiran (formerly AMG 890), Obicetrapib (TA-8995), and MK-0616, the atherosclerotic cardiovascular disease (ASCVD) therapeutics market is poised for significant growth and evolution through 2034. These investigational agents, which target previously under-addressed lipid and inflammatory pathways, are expected to complement or go beyond traditional statin therapy, offering new hope for patients with residual cardiovascular risk.

As these agents advance through clinical development and regulatory pathways, they are likely to expand treatment options for high-risk populations, improve LDL-C management, and reduce major adverse cardiovascular events (MACE). The growing focus on precision medicine, combined with increasing awareness, improved diagnostic tools, and a push for early intervention, is expected to further accelerate market momentum, positioning the ASCVD landscape for major therapeutic and commercial breakthroughs in the coming decade.

Atherosclerotic Cardiovascular Disease Market Drivers
• The global burden of ASCVD continues to grow due to sedentary lifestyles, poor dietary habits, and a steadily aging population, all contributing to higher rates of hypertension, diabetes, and dyslipidemia. This demographic and epidemiological shift is driving consistent demand for effective cardiovascular treatments.
• The development of next-generation lipid-lowering therapies like PCSK9 inhibitors, siRNA-based drugs (e.g., inclisiran), and CETP inhibitors (e.g., obicetrapib) is reshaping the treatment paradigm. These innovations, along with increased investments in cardiovascular R&D, are creating new opportunities for market expansion.

Atherosclerotic Cardiovascular Disease Market Barriers
• Advanced therapies, especially biologics and novel agents, often come with high price tags, limiting their adoption in low- and middle-income regions. Cost-effectiveness and reimbursement hurdles remain significant challenges for widespread market penetration.
• Long-term adherence to prescribed cardiovascular therapies and lifestyle changes remains suboptimal. Behavioral factors, medication side effects, and lack of disease awareness can lead to treatment discontinuation, undermining clinical outcomes and reducing overall market potential.

Scope of the Atherosclerotic Cardiovascular Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Atherosclerotic Cardiovascular Disease Companies: Merck Sharp & Dohme Corp, NewAmsterdam Pharma, Amgen Inc., and others.
• Key Atherosclerotic Cardiovascular Disease Therapies: Olpasiran (AMG 890), MK-0616, Obicetrapib (TA-8995), and others.
• Atherosclerotic Cardiovascular Disease Therapeutic Assessment: Atherosclerotic Cardiovascular Disease currently marketed, and Atherosclerotic Cardiovascular Disease emerging therapies.
• Atherosclerotic Cardiovascular Disease Market Dynamics: Atherosclerotic Cardiovascular Disease market drivers and Atherosclerotic Cardiovascular Disease market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• Atherosclerotic Cardiovascular Disease Unmet Needs, KOL's views, Analyst's views, Atherosclerotic Cardiovascular Disease Market Access and Reimbursement.

To learn more about atherosclerotic cardiovascular disease companies working in the treatment market, visit @ https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Atherosclerotic Cardiovascular Disease Market Report Introduction
2. Executive Summary for Atherosclerotic Cardiovascular Disease
3. SWOT analysis of Atherosclerotic Cardiovascular Disease
4. Atherosclerotic Cardiovascular Disease Patient Share (%) Overview at a Glance
5. Atherosclerotic Cardiovascular Disease Market Overview at a Glance
6. Atherosclerotic Cardiovascular Disease Disease Background and Overview
7. Atherosclerotic Cardiovascular Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Atherosclerotic Cardiovascular Disease
9. Atherosclerotic Cardiovascular Disease Current Treatment and Medical Practices
10. Atherosclerotic Cardiovascular Disease Unmet Needs
11. Atherosclerotic Cardiovascular Disease Emerging Therapies
12. Atherosclerotic Cardiovascular Disease Market Outlook
13. Country-Wise Atherosclerotic Cardiovascular Disease Market Analysis (2020-2034)
14. Atherosclerotic Cardiovascular Disease Market Access and Reimbursement of Therapies
15. Atherosclerotic Cardiovascular Disease Market Drivers
16. Atherosclerotic Cardiovascular Disease Market Barriers
17. Atherosclerotic Cardiovascular Disease Appendix
18. Atherosclerotic Cardiovascular Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.